Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
Portfolio Pulse from Vandana Singh
The FDA has expanded the approval of Sarepta Therapeutics Inc's (NASDAQ:SRPT) Elevidys to include individuals with Duchenne muscular dystrophy (DMD) who are at least four years old. This expansion is expected to lead to rapid uptake and substantial revenue growth for Sarepta. William Blair reiterates an Outperform rating with a fair value estimate of $210 per share. The approval is a significant milestone for Sarepta's DMD franchise and validates its gene therapy platform.
June 21, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's expanded approval of Sarepta's Elevidys to include more DMD patients is expected to lead to rapid uptake and substantial revenue growth. William Blair reiterates an Outperform rating with a fair value estimate of $210 per share.
The expanded approval significantly increases the potential patient population for Elevidys, leading to higher anticipated revenues. The positive analyst rating and fair value estimate further support a bullish outlook for SRPT.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100